Iqira Saeed1, Adam La Caze1, Markus W Hollmann2, Paul N Shaw1, Marie-Odile Parat3. 1. School of Pharmacy, University of Queensland, 20 Cornwall Street, Woolloongabba, Australia. 2. Department of Anaesthesiology, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands. 3. School of Pharmacy, University of Queensland, 20 Cornwall Street, Woolloongabba, Australia. m.parat@uq.edu.au.
Abstract
PURPOSE OF REVIEW: Opioids are administered to cancer patients although concerns have been raised that they may promote tumour growth or metastasis owing to their ability to suppress anti-cancer immunity. Tramadol has been reported to preserve or promote the immune response and may therefore be preferred to other opioids in cancer patients. We reviewed the literature documenting the immunomodulatory effects of tramadol. RECENT FINDINGS: Recent clinical evidence appears to confirm that tramadol possesses anti-inflammatory properties, and preserves some signalling cascades of the immune system relevant to anti-cancer defence. Tramadol is reported to promote or preserve immunity including natural killer cell activity which is important in anti-cancer defences.
PURPOSE OF REVIEW: Opioids are administered to cancer patients although concerns have been raised that they may promote tumour growth or metastasis owing to their ability to suppress anti-cancer immunity. Tramadol has been reported to preserve or promote the immune response and may therefore be preferred to other opioids in cancer patients. We reviewed the literature documenting the immunomodulatory effects of tramadol. RECENT FINDINGS: Recent clinical evidence appears to confirm that tramadol possesses anti-inflammatory properties, and preserves some signalling cascades of the immune system relevant to anti-cancer defence. Tramadol is reported to promote or preserve immunity including natural killer cell activity which is important in anti-cancer defences.
Authors: Thomas P Enggaard; Lars Poulsen; Lars Arendt-Nielsen; Kim Brøsen; Joachim Ossig; Søren H Sindrup Journal: Anesth Analg Date: 2006-01 Impact factor: 5.108
Authors: Robert B Raffa; Helmut Buschmann; Thomas Christoph; Gary Eichenbaum; Werner Englberger; Christopher M Flores; Torsten Hertrampf; Babette Kögel; Klaus Schiene; Wolfgang Straßburger; Rolf Terlinden; Thomas M Tzschentke Journal: Expert Opin Pharmacother Date: 2012-06-15 Impact factor: 3.889